[A case of breast cancer with multiple bone metastases demonstrating complete remission with high-dose toremifene therapy].
We report a 64-year-old woman who underwent mastectomy for stage II (T2N1M0) advanced breast cancer, in whom multiple spine metastases developed 18 months postoperatively. She received 6 cycles of CA (cyclophosphamide 500 mg/m2, ADM 50 mg/m2 3 wq) therapy and oral tamoxifen (20 mg/body) administration for adjuvant therapy. The multiple bone metastases of the spine were revealed by technetium bone scan. The level of serum tumor marker CA15-3 increased two times over the normal range 18 months after surgery. She also developed osteoporosis a few years later, so we selected high-dose toremifene administration (120 mg/body) as a second-line therapy. No adverse effects have occurred and bone metastases disappeared. Moreover, the tumor marker was also normalized 6 months after toremifene therapy started. It was shown that high-dose treatment of toremifene was useful for recurrent breast cancer with bone metastasis.
Saito
Yoshihito
Y
Dept. of Breast and Endocrine Surgery, Nihon University School of Medicine.
Amano
Sadao
S
Kashio
Mitsuhiko
M
Abe
Hideo
H
Kuboi
Youichi
Y
Sakurai
Kenichi
K
Aoki
Nobuhiko
N
Hata
Satoshi
S
Negishi
Nanao
N
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000556:secondary*; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D012074:Remission Induction; D017312:Toremifene / Q000008:administration & dosage*
D018931:Antineoplastic Agents, Hormonal; D017312:Toremifene